Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
To evaluate the benefits and harms of oral centrally acting antiobesity medicinal products in pivotal trials.
The European Medicines Agency and Federal Drug Administration websites, PubMed, and ClinicalTrials. gov were searched to identify pivotal trials used to gain marketing authorizations. Pivotal phase III trials on which marketing authorizations were based were included. The data were analyzed by using Cochrane Review Manager (RevMan), and ...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher copy:
- Copyright date:
If you are the owner of this record, you can report an update to it here: Report update to this record